Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IFNGR1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IFNGR1 (CD119) ECD-Fc Recombinant Protein High purity (>95%), Endotoxin controlled (<1 EU/μg). Sequence Verified. HEK293 expressed for native glycosylation. |
View IFNGR1 Products |
| Gene Delivery | IFNGR1 Promise-ORF / Lentivirus Full-length human IFNGR1 ORF for stable cell line construction and functional signaling validation. |
View IFNGR1 Products |
| Benchmark Ab | Anti-IFNGR1 Recombinant Antibody Recombinant positive control matching peer-reviewed clinical-grade sequences. |
View IFNGR1 Products |
| Validator | IFNGR1 siRNA Set Target-specific knockdown verification in human primary cells and cell lines. |
View IFNGR1 Products |
| Related Target A | IFNGR2 Obligate accessory chain for functional interferon-gamma receptor complex signaling. |
View IFNGR2 Products |
| Related Target B | IFNG (Interferon-gamma) The cognate cytokine ligand driving IFNGR1 receptor oligomerization and JAK/STAT activation. |
View IFNG Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species ortholog validation | Human, Cynomolgus, and Mouse IFNGR1 ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Subfamily counter-screening | Homologous receptor extracellular domains (e.g., IFNAR1, IFNAR2, IL10RB) strictly verified by mass spectrometry to eliminate cross-reactivity. |
| Lack of positive control references | Clinical-grade benchmark biosimilar antibodies included in the catalog for assay calibration. |
| Target specificity confirmation | Sequence-verified siRNA pools included to validate target-specific knockdown in cell-based screening. |
Live IFNGR1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IFNGR1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific constructs and cell therapy engineering. As first-generation therapies reach the clinic, the next wave of R&D is targeting IFNGR1 modulation to overcome immune checkpoint inhibitor resistance and treat hyper-inflammatory syndromes.
Originally characterized as the primary binding receptor for IFN-gamma, CD119 (IFNGR1) has emerged as a double-edged sword. In oncology, loss-of-function mutations or epigenetic silencing of IFNGR1 represents a major mechanism of acquired resistance to anti-PD-1 therapies, prompting research into downstream bypass pathways. Conversely, in severe autoimmune diseases, hemophagocytic lymphohistiocytosis (HLH), and graft-versus-host disease (GvHD), therapeutic blockade of the IFNGR1 pathway offers a potent strategy to halt cytokine storms.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Blocking Antibodies (mAbs) | Incyte, Novimmune | HLH, GvHD, Inflammatory Disorders | Neutralization Assay (Need high-purity, native glycosylated ECD-Fc) |
| Lentiviral Overexpression | Academic Medical Centers, Biotech Startups | Immuno-oncology, CAR-T Engineering | Stable cell line validation (Need Lentivirus Premade Particles for JAK/STAT reporter assays) |
| Small Molecule Inhibitors | Pfizer, Eli Lilly | Autoimmune Diseases | Selectivity Assay (Need mutant vs WT proteins to profile downstream JAK/STAT pathway selectivity) |